This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hegi, M. E. Articles by Gilbert, M. R. Search for Related Content PubMed PubMed Citation Articles by Hegi, M. E. Articles by Gilbert, M. R. Social Bookmarking                            What's this?

Correlation of O⁶-Methylguanine Methyltransferase (MGMT) Promoter Methylation With Clinical Outcomes in Glioblastoma and Clinical Strategies to Modulate MGMT Activity

Monika E. Hegi, Lili Liu, James G. Herman, Roger Stupp, Wolfgang Wick, Michael Weller, Minesh P. Mehta, Mark R. Gilbert

From the Laboratory of Tumor Biology and Genetics, Department of Neurosurgery, Centre Hospitalier Universitaire Vaudois and University of Lausanne; National Center of Competence in Research Molecular Oncology, Lausanne; Department of Neurology, University Hospital Zurich, Zurich, Switzerland; Division of Hematology/Oncology, Case Western Reserve University, Cleveland, OH; Department of Oncology–Cancer Biology, Johns Hopkins University School of Medicine, Baltimore, MD; Department of Neuro-Oncology, UniversitätsKlinikum Heidelberg, Heidelberg, Germany; Department of Human Oncology, University of Wisconsin Medical School, Madison, WI; and the Department of Neuro-Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX

Corresponding author: Monika E. Hegi, PhD, Laboratory of Tumor Biology and Genetics, Department of Neurosurgery BH-19-110, Centre Hospitalier Universitaire Vaudois and University of Lausanne, CH-1011 Lausanne, Switzerland; e-mail: monika.hegi{at}chuv.ch

Resistance to alkylating agents via direct DNA repair by O⁶-methylguanine methyltransferase (MGMT) remains a significant barrier to the successful treatment of patients with malignant glioma. The relative expression of MGMT in the tumor may determine response to alkylating agents, and epigenetic silencing of the MGMT gene by promoter methylation plays an important role in regulating MGMT expression in gliomas. MGMT promoter methylation is correlated with improved progression-free and overall survival in patients treated with alkylating agents. Strategies to overcome MGMT-mediated chemoresistance are being actively investigated. These include treatment with nontoxic pseudosubstrate inhibitors of MGMT, such as O⁶-benzylguanine, or RNA interference-mediated gene silencing of MGMT. However, systemic application of MGMT inhibitors is limited by an increase in hematologic toxicity. Another strategy is to deplete MGMT activity in tumor tissue using a dose-dense temozolomide schedule. These alternative schedules are well tolerated; however, it remains unclear whether they are more effective than the standard dosing regimen or whether they effectively deplete MGMT activity in tumor tissue. Of note, not all patients with glioblastoma having MGMT promoter methylation respond to alkylating agents, and even those who respond will inevitably experience relapse. Herein we review the data supporting MGMT as a major mechanism of chemotherapy resistance in malignant gliomas and describe ongoing studies that are testing resistance-modulating strategies.

Supported in part by Schering-Plough International (funding for medical editorial assistance).

Authors’ disclosures of potential conflicts of interest and author contributions are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				E. R. Gerstner, S. Yip, D. L. Wang, D. N. Louis, A. J. Iafrate, and T. T. Batchelor MGMT METHYLATION IS A PROGNOSTIC BIOMARKER IN ELDERLY PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA Neurology, November 3, 2009; 73(18): 1509 - 1510. [Full Text] [PDF]

				A. Takeshita, N. Inoshita, M. Taguchi, C. Okuda, N. Fukuhara, K. Oyama, K. Ohashi, T. Sano, Y. Takeuchi, and S. Yamada High incidence of low O6-methylguanine DNA methyltransferase expression in invasive macroadenomas of Cushing's disease Eur. J. Endocrinol., October 1, 2009; 161(4): 553 - 559. [Abstract] [Full Text] [PDF]

				W Rachinger, S Grau, M Holtmannspotter, J Herms, J-C Tonn, and F W Kreth Serial stereotactic biopsy of brainstem lesions in adults improves diagnostic accuracy compared with MRI only J. Neurol. Neurosurg. Psychiatry, October 1, 2009; 80(10): 1134 - 1139. [Abstract] [Full Text] [PDF]

				I. L.M. Candiloro and A. Dobrovic Detection of MGMT Promoter Methylation in Normal Individuals Is Strongly Associated with the T Allele of the rs16906252 MGMT Promoter Single Nucleotide Polymorphism Cancer Prevention Research, October 1, 2009; 2(10): 862 - 867. [Abstract] [Full Text] [PDF]

				A. Elias, M. D. Siegelin, A. Steinmuller, A. von Deimling, U. Lass, B. Korn, and W. Mueller Epigenetic Silencing of Death Receptor 4 Mediates Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Resistance in Gliomas Clin. Cancer Res., September 1, 2009; 15(17): 5457 - 5465. [Abstract] [Full Text] [PDF]

				M. E. Hegi, D. Sciuscio, A. Murat, M. Levivier, and R. Stupp Epigenetic Deregulation of DNA Repair and Its Potential for Therapy Clin. Cancer Res., August 15, 2009; 15(16): 5026 - 5031. [Abstract] [Full Text] [PDF]

				J. L. Clarke, F. M. Iwamoto, J. Sul, K. Panageas, A. B. Lassman, L. M. DeAngelis, A. Hormigo, C. P. Nolan, I. Gavrilovic, S. Karimi, et al. Randomized Phase II Trial of Chemoradiotherapy Followed by Either Dose-Dense or Metronomic Temozolomide for Newly Diagnosed Glioblastoma J. Clin. Oncol., August 10, 2009; 27(23): 3861 - 3867. [Abstract] [Full Text] [PDF]

				S. Yip, J. Miao, D. P. Cahill, A. J. Iafrate, K. Aldape, C. L. Nutt, and D. N. Louis MSH6 Mutations Arise in Glioblastomas during Temozolomide Therapy and Mediate Temozolomide Resistance Clin. Cancer Res., July 15, 2009; 15(14): 4622 - 4629. [Abstract] [Full Text] [PDF]

				R. Farcas, E. Schneider, K. Frauenknecht, I. Kondova, R. Bontrop, J. Bohl, B. Navarro, M. Metzler, H. Zischler, U. Zechner, et al. Differences in DNA Methylation Patterns and Expression of the CCRK Gene in Human and Nonhuman Primate Cortices Mol. Biol. Evol., June 1, 2009; 26(6): 1379 - 1389. [Abstract] [Full Text] [PDF]

				P. Giussani, L. Brioschi, R. Bassi, L. Riboni, and P. Viani Phosphatidylinositol 3-Kinase/AKT Pathway Regulates the Endoplasmic Reticulum to Golgi Traffic of Ceramide in Glioma Cells: A LINK BETWEEN LIPID SIGNALING PATHWAYS INVOLVED IN THE CONTROL OF CELL SURVIVAL J. Biol. Chem., February 20, 2009; 284(8): 5088 - 5096. [Abstract] [Full Text] [PDF]

				W. Wick, M. Platten, and M. Weller New (alternative) temozolomide regimens for the treatment of glioma Neuro-oncol, January 1, 2009; 11(1): 69 - 79. [Abstract] [Full Text] [PDF]